On the public citation graph

Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

https://doi.org/10.1128/aac.00116-08
0 signed · 187 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s10096-004-1128-2openalex-snapshot
Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection
inferredcites →https://doi.org/10.1007/s10156-006-0438-yopenalex-snapshot
Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia
inferredcites →https://doi.org/10.1007/s101560070006openalex-snapshot
Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
inferredcites →https://doi.org/10.1007/s15010-002-2131-0openalex-snapshot
In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model
inferredcites →https://doi.org/10.1016/j.diagmicrobio.2004.06.004openalex-snapshot
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia
inferredcites →https://doi.org/10.1016/j.diagmicrobio.2004.12.010openalex-snapshot
Initial management of candidemia at an academic medical center: Evaluation of the IDSA guidelines
inferredcites →https://doi.org/10.1016/j.idc.2006.06.007openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Antifungals
inferredcites →https://doi.org/10.1016/j.idc.2006.07.004openalex-snapshot
Invasive Candidiasis
inferredcites →https://doi.org/10.1056/nejm199411173312001openalex-snapshot
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
inferredcites →https://doi.org/10.1086/313749openalex-snapshot
Practice Guidelines for the Treatment of Candidiasis
inferredcites →https://doi.org/10.1086/504810openalex-snapshot
Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study
inferredcites →https://doi.org/10.1086/513615openalex-snapshot
Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality
inferredcites →https://doi.org/10.1086/513927openalex-snapshot
Correlation of In Vitro Fluconazole Susceptibility with Clinical Outcome for Severely Ill Patients with Oropharyngeal Candidiasis
inferredcites →https://doi.org/10.1093/clinids/24.2.235openalex-snapshot
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
inferredcites →https://doi.org/10.1128/aac.00296-07openalex-snapshot
Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia
inferredcites →https://doi.org/10.1128/aac.00420-08openalex-snapshot
Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method
inferredcites →https://doi.org/10.1128/aac.00474-06openalex-snapshot
Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia
inferredcites →https://doi.org/10.1128/aac.00741-06openalex-snapshot
In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of Fluconazole
inferredcites →https://doi.org/10.1128/aac.42.5.1105openalex-snapshot
Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis
inferredcites →https://doi.org/10.1128/aac.42.6.1512openalex-snapshot
Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans
inferredcites →https://doi.org/10.1128/aac.43.9.2116openalex-snapshot
Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model
inferredcites →https://doi.org/10.1128/aac.44.10.2715-2718.2000openalex-snapshot
Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole
inferredcites →https://doi.org/10.1128/aac.47.10.3165-3169.2003openalex-snapshot
In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model
inferredcites →https://doi.org/10.1128/aac.49.8.3171-3177.2005openalex-snapshot
Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
inferredcites →https://doi.org/10.1128/cmr.14.4.643-658.2001openalex-snapshot
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
inferredcites →https://doi.org/10.1128/cmr.19.2.435-447.2006openalex-snapshot
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
inferredcites →https://doi.org/10.1542/peds.65.1.187openalex-snapshot
National Committee for Clinical Laboratory Standards

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.5281/zenodo.13692340openalex-extracted
Fluconazole Loaded Ethosomes Gel and Liposomes Gel: An Updated Review for the Treatment of Deep Fungal Skin Infection
inferred← citeshttps://doi.org/10.1002/aoc.6687openalex-snapshot
Nickel N‐heterocyclic carbene complexes based on xanthines: Synthesis and antifungal activity on Candida sp.
inferred← citeshttps://doi.org/10.1002/cpt.2198openalex-snapshot
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
inferred← citeshttps://doi.org/10.1002/phar.1146openalex-snapshot
Antifungal Susceptibility Testing: A Primer for Clinicians
inferred← citeshttps://doi.org/10.1002/phar.1233openalex-snapshot
The Evolving Role of Antifungal Susceptibility Testing
inferred← citeshttps://doi.org/10.1002/phar.1470openalex-snapshot
Fluconazole Pharmacokinetics in a Morbidly Obese, Critically Ill Patient Receiving Continuous Venovenous Hemofiltration
inferred← citeshttps://doi.org/10.1007/978-1-4419-6640-7_5openalex-snapshot
Azoles
inferred← citeshttps://doi.org/10.1007/978-1-4419-6640-7_8openalex-snapshot
Antifungal Pharmacokinetics and Pharmacodynamics
inferred← citeshttps://doi.org/10.1007/978-1-4939-1304-6_10openalex-snapshot
Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis
inferred← citeshttps://doi.org/10.1007/978-2-8178-0389-0_7openalex-snapshot
De la bonne utilisation des antifongiques systémiques en réanimation
inferred← citeshttps://doi.org/10.1007/978-3-032-22660-0_48openalex-snapshot
Practical Pharmacokinetics and Pharmacodynamics
inferred← citeshttps://doi.org/10.1007/978-3-319-04220-6_14openalex-snapshot
Antimicrobial Agents, Drug Adverse Reactions and Interactions, and Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-28797-3_37openalex-snapshot
Yeast Infections After Haematopoietic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.1007/978-3-319-31398-6_1openalex-snapshot
Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT)
inferred← citeshttps://doi.org/10.1007/978-3-319-64113-3_3openalex-snapshot
Candida and Candidiasis
inferred← citeshttps://doi.org/10.1007/978-3-642-39432-4_15openalex-snapshot
15 Antifungal Pharmacokinetics
inferred← citeshttps://doi.org/10.1007/s00134-019-05866-wopenalex-snapshot
Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)
inferred← citeshttps://doi.org/10.1007/s10096-019-03611-1openalex-snapshot
The association between fluconazole dose and MIC with mortality and persistence in candidemia
inferred← citeshttps://doi.org/10.1007/s10096-021-04201-wopenalex-snapshot
Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy
inferred← citeshttps://doi.org/10.1007/s12281-009-0010-1openalex-snapshot
Clinical application of antifungal pharmacodynamics
inferred← citeshttps://doi.org/10.1007/s12281-010-0010-1openalex-snapshot
Using Antifungal Pharmacodynamics to Improve Patient Outcomes
inferred← citeshttps://doi.org/10.1007/s12281-010-0012-zopenalex-snapshot
Antifungal Dosing in Critically Ill Patients
inferred← citeshttps://doi.org/10.1007/s12281-010-0015-9openalex-snapshot
Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: Pharmacokinetic and Pharmacodynamic Considerations
inferred← citeshttps://doi.org/10.1007/s12281-010-0022-xopenalex-snapshot
Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?
inferred← citeshttps://doi.org/10.1007/s12281-010-0023-9openalex-snapshot
Antifungal Therapeutic Drug Monitoring
inferred← citeshttps://doi.org/10.1007/s12281-010-0026-6openalex-snapshot
Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection
inferred← citeshttps://doi.org/10.1007/s12281-011-0048-8openalex-snapshot
Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy
inferred← citeshttps://doi.org/10.1007/s12281-011-0050-1openalex-snapshot
Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring
inferred← citeshttps://doi.org/10.1007/s12281-019-00354-6openalex-snapshot
Antifungal Resistance Testing and Implications for Management
inferred← citeshttps://doi.org/10.1007/s12281-020-00391-6openalex-snapshot
Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins
inferred← citeshttps://doi.org/10.1007/s40265-014-0227-3openalex-snapshot
Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications
inferred← citeshttps://doi.org/10.1016/b978-0-12-815824-1.00002-0openalex-snapshot
Fungal infections—Background to specific fungal species
inferred← citeshttps://doi.org/10.1016/b978-0-323-04579-7.00149-0openalex-snapshot
Antifungal agents
inferred← citeshttps://doi.org/10.1016/b978-0-323-79525-8.00049-4openalex-snapshot
Clinical pharmacology of antiinfective drugs
inferred← citeshttps://doi.org/10.1016/b978-0-7020-6285-8.00156-8openalex-snapshot
Systemic Antifungal Agents
inferred← citeshttps://doi.org/10.1016/j.amjmed.2011.11.001openalex-snapshot
Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment
inferred← citeshttps://doi.org/10.1016/j.anrea.2023.11.003openalex-snapshot
Infections fongiques en réanimation
inferred← citeshttps://doi.org/10.1016/j.antinf.2016.01.002openalex-snapshot
Suivi thérapeutique pharmacologique des antifongiques : utile ?
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2022.121618openalex-snapshot
Rapid and high-throughput testing of antifungal susceptibility using an AIEgen-based analytical system
inferred← citeshttps://doi.org/10.1016/j.bjid.2016.09.009openalex-snapshot
Antifungal pharmacodynamics: Latin America's perspective
inferred← citeshttps://doi.org/10.1016/j.ccc.2010.11.001openalex-snapshot
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
inferred← citeshttps://doi.org/10.1016/j.ccm.2009.02.001openalex-snapshot
Overview of Antifungal Agents
inferred← citeshttps://doi.org/10.1016/j.clinthera.2016.08.001openalex-snapshot
Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury
inferred← citeshttps://doi.org/10.1016/j.cmi.2015.07.005openalex-snapshot
Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection
inferred← citeshttps://doi.org/10.1016/j.cmi.2017.01.014openalex-snapshot
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
inferred← citeshttps://doi.org/10.1016/j.cmi.2020.02.017openalex-snapshot
Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
inferred← citeshttps://doi.org/10.1016/j.colsurfb.2016.03.013openalex-snapshot
Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system
inferred← citeshttps://doi.org/10.1016/j.coph.2010.06.002openalex-snapshot
Antifungal therapy in invasive fungal infections
inferred← citeshttps://doi.org/10.1016/j.diagmicrobio.2010.01.002openalex-snapshot
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program
inferred← citeshttps://doi.org/10.1016/j.drup.2010.09.002openalex-snapshot
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
inferred← citeshttps://doi.org/10.1016/j.drup.2014.01.001openalex-snapshot
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
inferred← citeshttps://doi.org/10.1016/j.eimc.2010.08.005openalex-snapshot
Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010
inferred← citeshttps://doi.org/10.1016/j.eimc.2014.04.016openalex-snapshot
Training should be the first step toward an antifungal stewardship program
inferred← citeshttps://doi.org/10.1016/j.idc.2015.10.014openalex-snapshot
Update from the Laboratory
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2011.11.017openalex-snapshot
Invasive fungal infections in patients with cancer in the Intensive Care Unit
inferred← citeshttps://doi.org/10.1016/j.jiph.2021.11.002openalex-snapshot
Drug resistance in Candida albicans isolates and related changes in the structural domain of Mdr1 protein
inferred← citeshttps://doi.org/10.1016/j.jksus.2022.102072openalex-snapshot
Phytochemical analysis of Cymbopogon flexuosus (lemongrass) oil, its antifungal activity, and role in inhibiting biofilm formation in Candida albicans MTCC854
inferred← citeshttps://doi.org/10.1016/j.jmii.2023.08.014openalex-snapshot
Clinical impact of the combination of rapid species identification and antifungal stewardship intervention in adults with candidemia
inferred← citeshttps://doi.org/10.1016/j.matchemphys.2023.128382openalex-snapshot
Structural, optical and antifungal properties of the PMMA-ZnO nanocomposites: Potential applications in odontology
inferred← citeshttps://doi.org/10.1016/j.mgene.2017.04.006openalex-snapshot
High order interaction analysis of SNPs in PEDF (rs12150053, rs12948385) and EPO (rs1617640) genes with clinical determinants of type 2 diabetic retinopathy patients from south India
inferred← citeshttps://doi.org/10.1016/j.mycmed.2021.101206openalex-snapshot
Emerging issue of fluconazole-resistant candidemia in a tertiary care hospital of southern italy: time for antifungal stewardship program
inferred← citeshttps://doi.org/10.1016/j.riam.2011.06.004openalex-snapshot
Candidiasis invasora en un receptor de trasplante hepático: tratamiento antifúngico de rescate precoz
inferred← citeshttps://doi.org/10.1016/j.riam.2013.09.012openalex-snapshot
The oxidative stress response of the opportunistic fungal pathogen Candida glabrata
inferred← citeshttps://doi.org/10.1016/j.rmr.2016.08.008openalex-snapshot
Intérêt du suivi thérapeutique pharmacologique dans le cadre des infections pulmonaires
inferred← citeshttps://doi.org/10.1016/j.tca.2020.178806openalex-snapshot
Isothermal microcalorimetric determination of the inhibition of Candida species by antifungals
inferred← citeshttps://doi.org/10.1021/acsinfecdis.2c00249openalex-snapshot
PET Imaging of Active Invasive Fungal Infections with d -[5-11C]-Glutamine
inferred← citeshttps://doi.org/10.1051/matecconf/20166503004openalex-snapshot
Inhibitory Effect ofCratoxylum formosumGum onCandida glabrataand Itsα-mangostin Content
inferred← citeshttps://doi.org/10.1053/j.ackd.2012.10.004openalex-snapshot
Antimicrobial Dosing in Acute Renal Replacement
inferred← citeshttps://doi.org/10.1055/s-0039-1693704openalex-snapshot
Diagnosis and Treatment of Candidemia in the Intensive Care Unit
inferred← citeshttps://doi.org/10.1080/13696998.2017.1417312openalex-snapshot
Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China
inferred← citeshttps://doi.org/10.1080/14756366.2021.1906664openalex-snapshot
Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis
inferred← citeshttps://doi.org/10.1088/1755-1315/1271/1/012077openalex-snapshot
Antifungal effect of Pseudomonas azotoformans UICC B-91 metabolites on hyphal growth of Trichophyton mentagrophytes
inferred← citeshttps://doi.org/10.1093/infdis/jix239openalex-snapshot
The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
inferred← citeshttps://doi.org/10.1093/jac/dkag055openalex-snapshot
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
inferred← citeshttps://doi.org/10.1093/jac/dkq053openalex-snapshot
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
inferred← citeshttps://doi.org/10.1093/jac/dks482openalex-snapshot
Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study
inferred← citeshttps://doi.org/10.1093/jac/dku053openalex-snapshot
Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
inferred← citeshttps://doi.org/10.1093/jac/dku124openalex-snapshot
Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study
inferred← citeshttps://doi.org/10.1093/jac/dkx447openalex-snapshot
Overview of antifungal dosing in invasive candidiasis
inferred← citeshttps://doi.org/10.1093/med/9780198755388.003.0045openalex-snapshot
Principles of antifungal therapy
inferred← citeshttps://doi.org/10.1093/ofid/ofab444openalex-snapshot
Antifungal Susceptibility Testing: A Primer for Clinicians
inferred← citeshttps://doi.org/10.1097/01.qco.0000399603.91138.e7openalex-snapshot
Pharmacokinetic–pharmacodynamic optimization of triazole antifungal therapy
inferred← citeshttps://doi.org/10.1097/ftd.0b013e3181b20b40openalex-snapshot
A Rapid and Sensitive LC-MS/MS Method for Determination of Fluconazole in Human Plasma and Its Application in Infants with Candida Infections
inferred← citeshttps://doi.org/10.1097/ftd.0b013e31829591a7openalex-snapshot
Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method
inferred← citeshttps://doi.org/10.1097/mcc.0b013e32833e84d2openalex-snapshot
Epidemiology of invasive candidiasis
inferred← citeshttps://doi.org/10.1097/qco.0000000000000740openalex-snapshot
Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions
inferred← citeshttps://doi.org/10.1097/qco.0b013e3283184611openalex-snapshot
Therapeutic drug monitoring for triazoles
inferred← citeshttps://doi.org/10.1101/cshperspect.a019653openalex-snapshot
Antifungal Pharmacokinetics and Pharmacodynamics
inferred← citeshttps://doi.org/10.1111/imj.12597openalex-snapshot
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014
inferred← citeshttps://doi.org/10.1111/j.1439-0507.2011.02146.xopenalex-snapshot
Azole‐resistant Candida spp. – emerging pathogens?
inferred← citeshttps://doi.org/10.1111/j.1469-0691.2009.02913.xopenalex-snapshot
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
inferred← citeshttps://doi.org/10.1111/myc.13121openalex-snapshot
From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis
inferred← citeshttps://doi.org/10.1111/myc.13477openalex-snapshot
Drug repurposing against Candida auris: A systematic review
inferred← citeshttps://doi.org/10.1128/9781555817176.ch22openalex-snapshot
Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use
inferred← citeshttps://doi.org/10.1128/9781555817176.ch23openalex-snapshot
The Impact of Antifungal Drug Resistance in the Clinic
inferred← citeshttps://doi.org/10.1128/9781555819040.ch15openalex-snapshot
Yeasts
inferred← citeshttps://doi.org/10.1128/aac.00484-25openalex-snapshot
A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans
inferred← citeshttps://doi.org/10.1128/aac.00991-24openalex-snapshot
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections
inferred← citeshttps://doi.org/10.1128/aac.01102-12openalex-snapshot
Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations
inferred← citeshttps://doi.org/10.1128/aac.01279-12openalex-snapshot
Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
inferred← citeshttps://doi.org/10.1128/aac.01354-13openalex-snapshot
Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model
inferred← citeshttps://doi.org/10.1128/aac.01411-08openalex-snapshot
Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia
inferred← citeshttps://doi.org/10.1128/aac.01430-10openalex-snapshot
Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
inferred← citeshttps://doi.org/10.1128/aac.01607-13openalex-snapshot
Low but Sufficient Anidulafungin Exposure in Critically Ill Patients
inferred← citeshttps://doi.org/10.1128/aac.01643-25openalex-snapshot
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development
inferred← citeshttps://doi.org/10.1128/aac.01688-09openalex-snapshot
Evaluation by Data Mining Techniques of Fluconazole Breakpoints Established by the Clinical and Laboratory Standards Institute (CLSI) and Comparison with Those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
inferred← citeshttps://doi.org/10.1128/aac.01960-18openalex-snapshot
Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis
inferred← citeshttps://doi.org/10.1128/aac.02461-15openalex-snapshot
In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis
inferred← citeshttps://doi.org/10.1128/aac.02566-17openalex-snapshot
Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose
inferred← citeshttps://doi.org/10.1128/jcm.00937-12openalex-snapshot
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012
inferred← citeshttps://doi.org/10.1128/jcm.00946-09openalex-snapshot
Variation in Susceptibility of Bloodstream Isolates ofCandida glabratato Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007
inferred← citeshttps://doi.org/10.1128/jcm.01072-18openalex-snapshot
Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?
inferred← citeshttps://doi.org/10.1128/jcm.01391-08openalex-snapshot
Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program
inferred← citeshttps://doi.org/10.1128/jcm.02437-10openalex-snapshot
Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program
inferred← citeshttps://doi.org/10.1128/jcm.03044-13openalex-snapshot
Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species
inferred← citeshttps://doi.org/10.1128/microbiolspec.dmih2-0030-2016openalex-snapshot
Yeasts
inferred← citeshttps://doi.org/10.1155/2014/340586openalex-snapshot
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective
inferred← citeshttps://doi.org/10.11606/d.9.2021.tde-09062022-111717openalex-snapshot
Abordagem PK/PD para avaliar a efetividade do fluconazol nas infecções fúngicas causadas por >i /i< em pacientes queimados de UTI
inferred← citeshttps://doi.org/10.1177/0885066609355262openalex-snapshot
Invasive Fungal Infections in the ICU
inferred← citeshttps://doi.org/10.1177/1934578x241275798openalex-snapshot
In-vitro Evaluation of the Antifungal Property of Cold-Pressed Coconut oil Against Drug-Resistant Candida albicans and in-Silico Bioactivity Against Candidapepsin-2
inferred← citeshttps://doi.org/10.1185/03007995.2012.761134openalex-snapshot
Fungal diagnosis: how do we do it and can we do better?
inferred← citeshttps://doi.org/10.1185/03007995.2012.761136openalex-snapshot
Antifungal therapy: current concepts and evidence-based management
inferred← citeshttps://doi.org/10.1186/2047-783x-16-4-187openalex-snapshot
Epidemiology and antifungal resistance in invasive candidiasis
inferred← citeshttps://doi.org/10.1186/cc7964openalex-snapshot
Determinants of mortality in non-neutropenic ICU patients with candidaemia
inferred← citeshttps://doi.org/10.1186/s12879-015-0809-zopenalex-snapshot
How much European prescribing physicians know about invasive fungal infections management?
inferred← citeshttps://doi.org/10.1186/s13054-015-0758-3openalex-snapshot
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
inferred← citeshttps://doi.org/10.1310/hpj4206-578openalex-snapshot
Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy
inferred← citeshttps://doi.org/10.1371/journal.pone.0104702openalex-snapshot
Characteristics of Hospital-Acquired and Community-Onset Blood Stream Infections, South-East Austria
inferred← citeshttps://doi.org/10.1517/17425255.2011.615309openalex-snapshot
Pharmacokinetic evaluation of fluconazole in critically ill patients
inferred← citeshttps://doi.org/10.1586/17512433.2016.1172209openalex-snapshot
Therapeutic drug monitoring of anti-infective agents in critically ill patients
inferred← citeshttps://doi.org/10.18683/germs.2017.1104openalex-snapshot
Bibliometric analysis of literature on antifungal triazole resistance: 1980 – 2015
inferred← citeshttps://doi.org/10.21276/ap.2021.10.2.20openalex-snapshot
Strategies for the management of Candida albicans infection
inferred← citeshttps://doi.org/10.2146/ajhp090099openalex-snapshot
Significant publications on infectious diseases pharmacotherapy in 2008
inferred← citeshttps://doi.org/10.2147/ceor.s141548openalex-snapshot
"De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany
inferred← citeshttps://doi.org/10.2165/10898550-000000000-00000openalex-snapshot
Management of Invasive Candidiasis in the Intensive Care Unit
inferred← citeshttps://doi.org/10.2174/138920013804870583openalex-snapshot
Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
inferred← citeshttps://doi.org/10.21926/obm.transplant.1802009openalex-snapshot
Evolution in the Management of Invasive Fungal Infections in Liver Transplant Recipients
inferred← citeshttps://doi.org/10.2217/17460913.4.1.77openalex-snapshot
Pinpointing Prognostic Indicators of Fungal Infections in Transplant Patients
inferred← citeshttps://doi.org/10.22541/au.159769416.61783293openalex-snapshot
Current fluconazole dosing regimens in critically ill adults result in under-exposure during early therapy
inferred← citeshttps://doi.org/10.2515/therapie/2011009openalex-snapshot
Niveau de preuve du suivi thérapeutique pharmacologique du voriconazole
inferred← citeshttps://doi.org/10.2515/therapie/2011013openalex-snapshot
Niveau de preuve du suivi thérapeutique pharmacologique du fluconazole
inferred← citeshttps://doi.org/10.3109/13693780903208256openalex-snapshot
The impact of delaying the initiation of appropriate antifungal treatment forCandidabloodstream infection
inferred← citeshttps://doi.org/10.3111/13696998.2013.839948openalex-snapshot
De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemicCandidainfections
inferred← citeshttps://doi.org/10.3389/fcimb.2022.976033openalex-snapshot
Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis
inferred← citeshttps://doi.org/10.3390/jcm9092878openalex-snapshot
Challenges in Antifungal Therapy in Diabetes Mellitus
inferred← citeshttps://doi.org/10.3390/jof7010017openalex-snapshot
Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections
inferred← citeshttps://doi.org/10.3390/molecules19011085openalex-snapshot
Invasive Fungal Infections in the ICU: How to Approach, How to Treat
inferred← citeshttps://doi.org/10.3390/molecules26133881openalex-snapshot
Analysis of Volatile Molecules Present in the Secretome of the Fungal Pathogen Candida glabrata
inferred← citeshttps://doi.org/10.3390/molecules27123704openalex-snapshot
Low-Molecular Pyrazine-Based DNA Binders: Physicochemical and Antimicrobial Properties
inferred← citeshttps://doi.org/10.3390/ph14111130openalex-snapshot
The Antibacterial Synthetic Flavonoid BrCl-Flav Exhibits Important Anti-Candida Activity by Damaging Cell Membrane Integrity
inferred← citeshttps://doi.org/10.36472/msd.v10i4.924openalex-snapshot
Distribution and antifungal resistance rate of yeast isolated from various samples
inferred← citeshttps://doi.org/10.3904/kjm.2015.88.5.518openalex-snapshot
Invasive Fungal Infections in the Era of Antifungal Resistance
inferred← citeshttps://doi.org/10.4065/mcp.2011.0002openalex-snapshot
Introduction to the Symposium on Antimicrobial Therapy
inferred← citeshttps://doi.org/10.4065/mcp.2011.0247openalex-snapshot
Current Concepts in Antifungal Pharmacology
inferred← citeshttps://doi.org/10.4103/0022-3859.118036openalex-snapshot
Candidemia in intensive care unit patients
inferred← citeshttps://doi.org/10.4137/cmt.s8293openalex-snapshot
Impact of the New Clinical Breaking Points Proposed by the Clinical and Laboratory Standards Institute (CLSI) in the Antifungal Susceptibility Profile of Clinical Strains Isolated from Invasive Bloodstream Candida Spp. Infections in Spain
inferred← citeshttps://doi.org/10.5897/ajmr2017.8588openalex-snapshot
Production of novel antifungal compounds from actinomycetes isolated from waste dump soil in Western Uganda
inferred← citeshttps://doi.org/10.6084/m9.figshare.15095098openalex-snapshot
Additional file 1 of Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
inferred← citeshttps://doi.org/10.6084/m9.figshare.15095101openalex-snapshot
Additional file 2 of Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
inferred← citeshttps://doi.org/10.7727/wimj.2012.140openalex-snapshot
Is Timely and Appropriate Antifungal Drug Enough for Survival of Adult Cases with Candidaemia? Five-year Experience
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.